Bio-pharmaceutical companies usually make for some very high risk investments. This is because there are a number of factors that cannot be predicted accurately.The valuations skyrocket on drug approvals, but the actual performance in the market is an entirely different story. The following three stock have seen heavy institutional selling in the last few months, and I believe investors should stay away from them for the time.
Cambrex Corporation more »
Healthcare stocks, in general, have had a nice rally recently, with many shares outperforming the S&P 500 Index. Despite the rally, some stocks in this sector are still attractively priced. Three that caught my eye also have good growth prospects.
The healthcare sector is broad and covers a wide range of industries, including medical equipment, pharmaceuticals, and biotech. That aspect is important to keep in mind, particularly when examining more »
It's time to give your portfolio a little treat for its stocking. But shopping for a stocking stuffer amid the world of 18,000 small cap stocks is no little feat. Most of these are truly just lumps of coal, but screening for small caps that actually have earnings, growth, and good management narrows it down considerably. Small caps are also lightly covered by analysts and the financial press more »